Ferroptosis & Aging: The Missing Link in Cardiometabolic and Liver Disease
Ferroptosis is an emerging form of cell death that is gaining attention as a key driver of aging and chronic disease. First described by researchers at Columbia University in 2012, more than 20,000 peer-reviewed studies have since explored its role in accelerating aging, as well as the onset and severity of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, and cognitive decline.
In this live conversation, Dr. Kara Fitzgerald and Dr. Stephanie Venn-Watson will break down the pathophysiology of ferroptosis, its downstream effects across metabolic, liver, cardiovascular, and cognitive health, and what this means for clinical practice.
By the end of this presentation, participants will:
- Understand the pathophysiology of ferroptosis and its downstream effects across metabolic, liver, cardiovascular, and cognitive health.
- Know key clinical biomarkers to detect patients with ferroptosis and monitor response to interventions.
- Learn currently studied approaches to managing ferroptosis and associated iron overload, including mounting evidence that ferroptosis is part of a treatable nutritional deficiency syndrome.
Register today to learn how the reversal of key nutritional deficiencies are emerging as a means to treat ferroptosis, slow biological aging rates, and stem downstream cardiometabolic and liver complications.
Live attendees will have the opportunity to participate in Q&A, and all registrants will be notified when the replay is available.
Sign up for free below*
Enroll to be a healthcare provider partner and for more education at www.fatty15clinic.com and get 15% off your first wholesale order
Disclaimer: This event is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider.
Stephanie Venn-Watson, DVM, MPH. Co-Founder and CEO of fatty15
Dr. Stephanie Venn-Watson is co-founder and co-CEO of Seraphina Therapeutics. As a veterinary epidemiologist who has worked for the World Health Organization, DARPA and the U.S. Navy, Steph has authored over 80 peer-reviewed scientific papers and has over 70 patents.
Stephs’ discoveries have been featured on NPR Science Friday, BBC, NBC, and National Geographic; and her groundbreaking discoveries around the health benefits of C15:0 are the topic of her recently released best-selling Simon & Schuster book, The Longevity Nutrient. Steph is a recipient of FastCompany’s World Changing Idea in Wellness, is an Albert Schweitzer Fellow for Life, and was recently named a 2025 CNBC Changemaker.
